We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Doximity (DOCS) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Doximity (DOCS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Doximity is a member of the Medical sector. This group includes 1022 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Doximity is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for DOCS' full-year earnings has moved 9.3% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, DOCS has gained about 89% so far this year. Meanwhile, the Medical sector has returned an average of 2.4% on a year-to-date basis. This shows that Doximity is outperforming its peers so far this year.
AxoGen (AXGN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 103.5%.
The consensus estimate for AxoGen's current year EPS has increased 10.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Doximity belongs to the Medical Services industry, a group that includes 59 individual companies and currently sits at #133 in the Zacks Industry Rank. This group has lost an average of 5.6% so far this year, so DOCS is performing better in this area.
On the other hand, AxoGen belongs to the Medical - Instruments industry. This 86-stock industry is currently ranked #55. The industry has moved +6.6% year to date.
Investors with an interest in Medical stocks should continue to track Doximity and AxoGen. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Doximity (DOCS) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Doximity (DOCS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Doximity is a member of the Medical sector. This group includes 1022 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Doximity is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for DOCS' full-year earnings has moved 9.3% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, DOCS has gained about 89% so far this year. Meanwhile, the Medical sector has returned an average of 2.4% on a year-to-date basis. This shows that Doximity is outperforming its peers so far this year.
AxoGen (AXGN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 103.5%.
The consensus estimate for AxoGen's current year EPS has increased 10.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Doximity belongs to the Medical Services industry, a group that includes 59 individual companies and currently sits at #133 in the Zacks Industry Rank. This group has lost an average of 5.6% so far this year, so DOCS is performing better in this area.
On the other hand, AxoGen belongs to the Medical - Instruments industry. This 86-stock industry is currently ranked #55. The industry has moved +6.6% year to date.
Investors with an interest in Medical stocks should continue to track Doximity and AxoGen. These stocks will be looking to continue their solid performance.